Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
124.51
+2.10 (+1.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Analyst Ratings for Sarepta Therapeutics
September 08, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
September 08, 2022
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
Via
Benzinga
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
September 06, 2022
Via
Benzinga
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
August 30, 2022
Not all shares are slowing down alongside the industry group.
Via
Investor's Business Daily
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
August 08, 2022
Via
Benzinga
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
August 08, 2022
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and...
Via
Benzinga
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
August 03, 2022
Via
Benzinga
Duchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst
July 29, 2022
Via
Benzinga
Sarepta (SRPT) Stock Gains on FDA News
July 29, 2022
Sarepta Therapeutics (SRPT) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment.
Via
InvestorPlace
Sarepta Therapeutics: Q2 Earnings Insights
August 02, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Sarepta Therapeutics...
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sarepta Therapeutics Earnings Preview
August 01, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Sarepta...
Via
Benzinga
Chevron, Amazon And Some Other Big Gainers From Friday
August 01, 2022
U.S. stocks closed higher on Friday, with the Dow Jones jumping more than 300 points. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Where Sarepta Therapeutics Stands With Analysts
June 24, 2022
Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Earnings Scheduled For August 2, 2022
August 02, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
July 29, 2022
Via
Benzinga
Where Sarepta Therapeutics Stands With Analysts
July 29, 2022
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Apple, Amazon And Some Other Big Stocks Recording Gains On Friday
July 29, 2022
Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by CCNB shareholders.
Via
Benzinga
Exxon Mobil (XOM) Stock Pops on Record Profits
July 29, 2022
Exxon Mobil (XOM) stock is rising on Friday following the release of its earnings report for the second quarter of the year.
Via
InvestorPlace
CENN Stock Alert: Cenntro Invests in E-Cargo Designer
July 29, 2022
Cenntro (CENN) stock is on the move Friday as investors react to news of the electric vehicle (EV) company acquiring a stake in Antric.
Via
InvestorPlace
Sarepta Intents To Seek Accelerated Approval For Gene Therapy Candidate
July 29, 2022
Sarepta Therapeutics (NASDAQ: SRPT) announced its intention to submit Biologics License Application (BLA) seeking accelerated approval for SRP-9001 to treat ambulant individuals with Duchenne muscular...
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 20, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew
July 12, 2022
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 07, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Investors Search for Clues in Economic Data, Recession Signals
July 06, 2022
Stocks are extending this morning's quiet losses, as investors continue to keep an eye on signs of an oncoming recession.
Via
Talk Markets
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
July 06, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
June 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study
June 23, 2022
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular...
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.